Immatics

Despite a forecast of rain, the clouds cleared just in time for the Immatics summer party. 🌍 Immatics employees from all across Germany, and some from our site in Houston, recently gathered at the facility in Tübingen for a fantastic evening of fun, food and festivities. 🎉 From playing giant games and solving riddles during a treasure hunt to being captivated by magic tricks, it was great to have the team all together to celebrate our hard work, the new Campus Sternwarte facility and the summer season. We can’t wait for our next team get-together! #TeamBuilding #Biotech #CorporateEvents #WorkHardPlayHard #TeamCelebration #EmployeeAppreciation

Last month, the European Medical Students’ Association (EMSA) hosted an event in Tübingen, Germany. Andrea Mayer-Mokler, Vice President Global Head of Clinical Sciences at Immatics, was invited to present the company to a group of medical students. During her presentation, Andrea shared Immatics’ story and emphasized how physicians are instrumental in moving innovative treatments from bench to bedside and can facilitate patient access to clinical trials. Thank you, EMSA, for this opportunity to connect with future leaders in the medical field. Together, we can make a difference in the lives of cancer patients. #biotech #EuropeanMedicalOrganizations #clinicaltrials #cancer

At Immatics, we know that “AI is where the data is®.” With this guiding principle, our team was thrilled to attend Cyber Valley's Opening, Community Expo & AI Incubator Demo Day in Stuttgart, Germany. Cyber Valley, Europe’s largest research consortium in artificial intelligence, hosted an insightful event that brought together innovators in this rapidly evolving field. We were excited to be part of the dialogue on how AI can transform industries and drive progress. But how do we incorporate AI into our work at Immatics? Learn about our immunoinformatics platform, XCUBE™, here: https://lnkd.in/evpdHPyy #bettertogether #artificialintelligence #AI #biotech

Did you know that nearly every five minutes, a person is diagnosed with one of the five gynecological cancers?* Our Director Clinical Development, Olga Veremchuk, Director Clinical Sciences, Sabine Kastner, and Associate Director Clinical Sciences, Diego Alcoba, Ph.D., are representing Immatics at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy. Among a variety of topics, the congress will include sessions on novel therapeutic strategies for rare gynecological cancers. At Immatics, we’re advancing the fight against solid tumors cancers with our novel cell and bispecific immunotherapies. Our pipeline includes product candidates targeting PRAME, one of the most promising and prevalent peptides presented on the surface of various solid tumors, including ovarian and uterine cancers. We also started expanding our clinical footprint for our second-generation cell therapy, IMA203CD8, outside of melanoma to address a broader patient population with a particular focus on ovarian and uterine cancers. Our mission is to deliver the power of T cells to cancer patients. #ESMOGynae24 #ESMO #CancerCare #CancerResearch #Biotech #Immunotherapy *According to The Foundation for Women's Cancer

June is Cancer Immunotherapy Month and shines a spotlight on how immunotherapy approaches are revolutionizing cancer treatment. In the last decade alone, advancements in cancer immunotherapy, such as CAR-T therapy, have significantly changed the treatment options and survival outcomes for patients with a range of cancers. Even in the last six months, substantial progress has been made with the FDA’s approval of the first-ever cell therapy for solid tumors. With these major strides in the field paving the path for future innovation and novel treatments, we are greatly encouraged as we gear up to begin a registration-enabling Phase 2/3 trial for our lead cell therapy candidate, IMA203, in metastatic melanoma patients. What does immunotherapy look like at Immatics? Check out this video that summarizes our therapeutic approach here: https://lnkd.in/d2_Bzrrj #Immune2Cancer #Immunotherapy #Immunooncology #Celltherapy #Cancer #Bispecifics

Last week, students from the NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals eXperience Program had a chance to visit our Immatics facility in Stafford, Texas. The program is hosted by the UH Cullen College of Engineering - Technology Division and promotes workforce diversity in biomanufacturing industries. Students from UH and other U.S. universities are invited to participate. The students began the day with a special welcome speech from our CEO, Harpreet Singh, and afterwards heard from speakers of various departments explain their roles and contributions to improving the lives of cancer patients. To end their visit, students were led on an engaging and informative tour of the facility by Harold Woods and Julie Nobles Thank you, University of Houston, for giving our Immatics team members the opportunity to share and, hopefully, inspire a few young minds to become a part of the biotech industry! #biotech #diversity #biopharmaceuticals #cancer #studentexperience #STEM #cullencollege #uhtechnology

Did you tune in to our CEO, Harpreet Singh's, fireside chat at Jefferies Healthcare Conference last week? If not, or if you’d like to watch the presentation again, click here: https://lnkd.in/dd_wtx48 #JefferiesHealthcare #Biotech #CompanyPresentation #Oncology #Cancer #Melanoma

Interested in learning more about autologous cell therapy process development? On Wednesday, June 12 from 1:30 - 2:00 pm ET, Senior Scientist, Justin Gunesch, Ph.D., will share insights on “Starting Material for Autologous Cell Therapies” at the Process Development for Cell Therapies Summit. Learn more about Justin’s talk and other summit details here: https://lnkd.in/drvQ6PRc #ProcessDevelopment #CellTherapy #CancerTreatment #LifeSciences #Biotech #CellTherapy

That’s a wrap on the American Society of Clinical Oncology (ASCO) 2024! The Immatics team had an outstanding time onsite at the annual conference in Chicago. This year’s theme was, “The Art and Science of Cancer Care: From Comfort to Cure.” Building on that theme, these are the Immatics team’s top takeaways from ASCO 2024: 💡There is still a high unmet medical need for checkpoint refractory patients and new advancements are crucial. 💡The use of ipilimumab and nivolumab in the neoadjuvant setting is a new standard for resectable stage 3 melanoma. 💡We were pleased to hear our lead cell therapy candidate, IMA203, mentioned in several melanoma talks. All in all, it’s been great to connect with other oncology professionals as we strive to bring novel immunotherapies to cancer care. #ASCOChicago #ASCO24 #healthcare #research #cancer #oncology #biotech

Immatics CEO, Harpreet Singh, and the Immatics team will be attending the Jefferies Healthcare Conference in New York from June 5 – 6, 2024. Be sure to also join Harpreet online on Wednesday, June 5th from 9:00 – 9:25 am ET for a fireside chat. To access the fireside chat webcast, click here: https://lnkd.in/dgtQJctD #JefferiesHealthcare #healthcare #biotechnology #oncology #cancer